Amgen 10-Qquarter ended 2026-09-30

Executive Summary

Amgen sells prescription medicines for patients with serious diseases, earning revenue from product sales, royalties and commercial partnerships. It is expanding newer medicines—including Repatha, UPLIZNA and IMDELLTRA/IMDYLLTRA—and investing in clinical programs and manufacturing as older franchises lose exclusivity or face government-set prices. Q3 revenue grew 8.5%, showing that growth brands are more than offsetting erosion in Prolia and XGEVA, although lower amortization and prior-year impairments also substantially boosted reported profit growth. The investor question is whether this portfolio transition can sustain growth while absorbing pricing pressure, TAVNEOS’s regulatory challenge and potentially large tax payments.

What's Happening in the Business

Volume, rather than pricing, drove growth. Product-sales volume increased 8% in Q3 vs 10% over nine months, while lower net prices partly offset demand. Repatha, TEZSPIRE, UPLIZNA and IMDELLTRA/IMDYLLTRA led the expansion. Conversely, biosimilar launches reduced both volume and prices for Prolia and XGEVA; management expects further erosion through 2026.

The next growth opportunities extend beyond current indications. Amgen reported positive Phase 3 results for TEZSPIRE in eosinophilic esophagitis and dazodalibep in Sjögren’s disease, alongside positive survival results for IMDELLTRA/IMDYLLTRA plus IMFINZI in first-line maintenance small-cell lung cancer. Repatha gained an expanded European cardiovascular-risk-reduction indication. These developments support broader use, but clinical success does not itself establish reimbursement or commercial demand.

Amgen is committing more resources to future products and supply. Nine-month R&D increased 11% to $5.70B, including spending on MariTide and earlier-stage programs. Manufacturing-capacity investment lifted capital expenditures 49% to $1.81B; management estimates ≈$2.6B for full-year capital projects.

TAVNEOS moved in the opposite direction: the European Commission revoked its authorization in 8/2026, while the FDA’s proposed withdrawal remains unresolved. Amgen requested a hearing and submitted supporting evidence; the medicine remains available in the United States pending that process.

Key Financial Highlights

• Profit quality: Prior-year Otezla impairments were $400M in Q3 and $1.2B over nine months. Finite-lived intangible amortization fell to $889M from $1.10B in Q3; these accounting comparisons are not equivalent to new demand.
• Investment gains: Unrealized gains on BeOne Medicines were $1.5B vs $1.9B in Q3 and $1.2B vs $3.0B over nine months. Market movements therefore remain a substantial influence on GAAP earnings.
• Cash generation: Nine-month net income trailed OCF because earnings include noncash expenses and investment gains, alongside working-capital effects; OCF’s improvement also reflects the prior-year final $1.8B repatriation-tax payment. FCF after capital expenditures was $8.62B, up 21%.
• Capital allocation: Nine-month dividends were $4.08B vs $3.84B, with no repurchases. Shares outstanding increased 0.4% from year-end. Cash reached $13.2B against total debt carrying value of $54.0B, leaving substantial leverage despite stronger liquidity.

Risk Assessment

• Pricing and exclusivity: Biosimilars are eroding Prolia and XGEVA, while Medicare price setting already affects ENBREL and begins for Otezla on 1/1/2027; expanding rebate obligations could further weaken realized prices.
• TAVNEOS withdrawal: Safety concerns and FDA challenges to efficacy evidence threaten continued U.S. approval and its $2.2B U.S. developed-product-technology carrying value.
• Tax litigation: IRS claims for 2010–2015 total ≈$8.7B of additional tax plus interest and $2.0B of penalties before potential offsets; later years are also disputed, and payments could substantially exceed accruals.
• Balance-sheet exposure: Heavy debt and negative tangible common equity of $(23.8)B leave less protection against acquisition-asset impairments or large legal and tax payments.

What to Watch

• Growth-brand durability: UPLIZNA and IMDELLTRA/IMDYLLTRA are expanding rapidly; sustained volume growth and broader approved uses would validate the transition, while slowing uptake would expose legacy erosion.
• Legacy pricing: Watch whether growth products continue covering Prolia and XGEVA losses as Otezla enters Medicare price setting; ENBREL’s nine-month net price already fell 19%.
• TAVNEOS outcome: Continued U.S. marketing depends on the unresolved FDA process; retained approval would preserve opportunity, while withdrawal could trigger impairment and lost sales.
• Tax resolution: Management expects no decision before late 2026 or early 2027; later filings should establish whether offsets and court outcomes contain the cash burden or force materially larger payments.